Feedback / Questions
ABBV-668 - AbbVie
ABBV-668: Data from P2 trial (NCT05570006) for moderate to severe ulcerative colitis in 2025
(AbbVie)
-
Feb 2, 2024 -
Q4 2023 Results
P2 data
•
Inflammatory Bowel Disease • Ulcerative Colitis
https://investors.abbvie.com/static-files/aefa6da8-17b6-4527-906f-bebc7aab2d5d
Feb 2, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious